Contact: Brandyn Bissinger [email protected]
Emerging agents like Tirzepatide, which activates both GLP-1 and GIP receptors, and Orforglipron, a nonpeptide oral GLP-1 agonist in phase 2 trials, further expand the therapeutic potential of this class (23)(24)
I love how it gives me a natural boost without any jitters
However, human clinical evidence is still limited, and larger, well-controlled trials are needed to clarify safety, efficacy, and appropriate use
Our clinical flow often looks like this: Baseline optimization: hydration, protein intake, sleep, circadian exposure to light, movement, and stress reduction
Al AhmadATaboadaCBGassmannMOgunsholaOO